Skip to main content

Advertisement

SpringerLink
Log in

Multimodality Therapy of Patients with Refractory Meningiomas

  • Neuro-oncology (GJ Lesser, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Recurrent and refractory meningiomas are a clinical challenge and treatment at the time of recurrence is not well delineated. Treatment with surgery and/or radiation remain the mainstay, but each has their limitations and risks. The search for an adjuvant systemic therapy continues and as many of the initially promising approaches have not had reproducible responses. Bevacizumab has shown some efficacy in controlling recurrent disease and could be useful in disease that is multifocal or in close proximity to critical structures. Other targeted therapies, as well as immunotherapy, are being studied and trials are in development. Though we are hopeful that these novel therapies will benefit patients with refractory meningiomas, we approach them with some trepidation. This is due to prior failures of immunotherapy and targeted therapy in central nervous system disease. In addition, there is known difficulty in developing trials and assessing response with these slow-growing tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ostrom QT, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62.

    Article  Google Scholar 

  2. • Proctor DT, et al. Towards molecular classification of meningioma: evolving treatment and diagnostic paradigms. World Neurosurg. 2018;119:366–73 Recent review with insight into future direction of meningioma management.

    Article  Google Scholar 

  3. •• Wen PY, et al. Medical therapies for meningiomas. J Neurooncol. 2010;99(3):365–78 Review of medical management of new and recurrent meningimoas.

    Article  CAS  Google Scholar 

  4. Aizer AA, et al. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015;121(24):4376–81.

    Article  Google Scholar 

  5. Sughrue ME, et al. Outcome and survival following primary and repeat surgery for World Health Organization grade III meningiomas. J Neurosurg. 2010;113(2):202–9.

    Article  Google Scholar 

  6. Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol. 2010;99(3):393–405.

    Article  Google Scholar 

  7. Pereira, B. J. A., et al.. Impact of radiotherapy in atypical meningioma recurrence: literature review. Neurosurg Rev. 1437–2320. 2018;2018 Mar 19. https://doi.org/10.1007/s10143-018-0959-8.

  8. Harris AE, et al. The effect of radiosurgery during management of aggressive meningiomas. Surg Neurol. 2003;60(4):298–305; discussion 305.

    Article  Google Scholar 

  9. Huffmann BC, Reinacher PC, Gilsbach JM. Gamma knife surgery for atypical meningiomas. J Neurosurg. 2005;102(Suppl):283–6.

    Article  Google Scholar 

  10. Kano H, et al. Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol. 2007;84(1):41–7.

    Article  Google Scholar 

  11. Rogers L, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4–23.

    Article  Google Scholar 

  12. Kim D, et al. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg. 2018;128(4):1123–32.

    Article  Google Scholar 

  13. Goldbrunner R, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9):e383–91.

    Article  Google Scholar 

  14. Nabors LB, et al. Central nervous system cancers, Version 1.2015. J Natl Compr Canc Netw. 2015;13(10):1191–202.

    Article  CAS  Google Scholar 

  15. Claus EB, et al. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57(6):1088–95; discussion 1088–95.

    Article  Google Scholar 

  16. Magill, S. T., et al.. Surgical outcomes after reoperation for recurrent non-skull base meningiomas. J Neurosurg. 2018;2018 Nov 1:1–9. https://doi.org/10.3171/2018.6.JNS18118.

  17. Magill, S. T., et al.. Surgical outcomes after reoperation for recurrent skull base meningiomas. J Neurosurg. 2018;2018 Apr 1:1–8. https://doi.org/10.3171/2017.11.JNS172278.

  18. Vera E, et al. A review of stereotactic radiosurgery practice in the management of skull base meningiomas. J Neurol Surg B Skull Base. 2014;75(3):152–8.

    Article  Google Scholar 

  19. Lin AJ, et al. Radiologic response and disease control of recurrent intracranial meningiomas treated with reirradiation. Int J Radiat Oncol Biol Phys. 2018;102(1):194–203.

    Article  Google Scholar 

  20. Minniti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol. 2009;4:42.

    Article  Google Scholar 

  21. Wojcieszynski AP, et al. Reirradiation of recurrent meningioma. J Clin Neurosci. 2012;19(9):1261–4.

    Article  Google Scholar 

  22. Kim M, et al. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery. Clin Neurol Neurosurg. 2017;153:93–101.

    Article  Google Scholar 

  23. •• Chamberlain MC, Barnholtz-Sloan JS. Medical treatment of recurrent meningiomas. Expert Rev. Neurother. 2011;11(10):1425–32 Review of medical management of recurrent meningiomas.

    Article  CAS  Google Scholar 

  24. Koide SS. Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med. 1998;43(7):551–60.

    CAS  PubMed  Google Scholar 

  25. Grunberg SM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74(6):861–6.

    Article  CAS  Google Scholar 

  26. Ji Y, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015;33(34):4093–8.

    Article  CAS  Google Scholar 

  27. Markwalder TM, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomas--a pilot study. Surg Neurol. 1985;24(3):245–9.

    Article  CAS  Google Scholar 

  28. Goodwin JW, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75–7.

    Article  CAS  Google Scholar 

  29. Madaan K, Kaushik D, Verma T. Hydroxyurea: a key player in cancer chemotherapy. Expert Rev. Anticancer Ther. 2012;12(1):19–29.

    Article  CAS  Google Scholar 

  30. Schrell UM, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86(5):840–4.

    Article  CAS  Google Scholar 

  31. Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18(5):495–9.

    Article  CAS  Google Scholar 

  32. Mason WP, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97(2):341–6.

    Article  CAS  Google Scholar 

  33. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9(2):156–8.

    Article  Google Scholar 

  34. Swinnen, L. J., et al.. Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). 27(15_suppl): 2063–3.

  35. Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol. 2011;104(3):765–71.

    Article  CAS  Google Scholar 

  36. Wilson CB. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture. J Neurosurg. 1994;81(5):666–75.

    Article  CAS  Google Scholar 

  37. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996;84(5):733–6.

    Article  CAS  Google Scholar 

  38. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62(7):1210–2.

    Article  CAS  Google Scholar 

  39. Koper JW, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer. 1991;27(4):416–9.

    Article  CAS  Google Scholar 

  40. Kaba SE, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40(2):271–5.

    Article  CAS  Google Scholar 

  41. Muhr C, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7(8):2269–76.

    CAS  PubMed  Google Scholar 

  42. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113(8):2146–51.

    Article  CAS  Google Scholar 

  43. Arena S, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004;66(1–2):155–66.

    Article  Google Scholar 

  44. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969–73.

    Article  CAS  Google Scholar 

  45. Simo M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol. 2014;73(5):919–23.

    Article  CAS  Google Scholar 

  46. Norden AD, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015;84(3):280–6.

    Article  CAS  Google Scholar 

  47. Pistolesi S, et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol. 2004;30(2):118–25.

    Article  CAS  Google Scholar 

  48. Nayak L, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93.

    Article  CAS  Google Scholar 

  49. Lou E, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63–70.

    Article  CAS  Google Scholar 

  50. • Franke AJ, et al. Role of bevacizumab for treatment-refractory meningiomas: a systematic analysis and literature review. Surg Neurol Int. 2018;9:133 Recent comprehensive review of bevacizumab use in recurrent meningioma.

    Article  Google Scholar 

  51. Grimm, S. A., et al.. Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. 33(15_suppl): 2055–5.

  52. • Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44(4):E3 Recent paper with discussion on future direction of meningioma management.

    Article  Google Scholar 

  53. Shih KC, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol. 2016;129(2):281–8.

    Article  CAS  Google Scholar 

  54. Kaley TJ, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116–21.

    Article  CAS  Google Scholar 

  55. Wen PY, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01–08). Neuro Oncol. 2009;11(6):853–60.

    Article  CAS  Google Scholar 

  56. Reardon DA, et al. Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012;106(2):409–15.

    Article  CAS  Google Scholar 

  57. Du Z, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6(7):4704–16.

    Article  Google Scholar 

  58. Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy success. Science. 2015;350(6257):158–9.

    Article  CAS  Google Scholar 

  59. Brastianos PK, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285–9.

    Article  CAS  Google Scholar 

  60. Clark VE, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077–80.

    Article  CAS  Google Scholar 

  61. Graillon, T., et al.. P11.11Aggressive Meningiomas: In vitro study of the combination pasireotideeverolimus vs. octreotide everolimus." Neuro-Oncology 18(suppl_4): iv68–iv68. https://doi.org/10.1093/neuonc/now188.242.

    Article  Google Scholar 

  62. Graillon T, et al. P11.11 Aggressive meningiomas: In vitro study of the combination pasireotide-everolimus vs. octreotide everolimus. Neuro-Oncology. 2016;18(suppl_4):iv68-iv68.

    Google Scholar 

  63. Gavrilovec I, et al. ACTR-43. Pilot study of optune (novottf-100a) for recurrent atypical and anaplastic meningioma. Neuro-Oncology. 2016;18(suppl_6):vi11-vi11.

    Google Scholar 

  64. Le DT, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  Google Scholar 

  65. Huang RY, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019;21(1):26–36.

    Article  Google Scholar 

  66. Kaley T, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16(6):829–40.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neuro-Oncology, School of Medicine, University of Virginia, PO Box 800432, Charlottesville, VA, 22908, USA

    Haroon Ahmad MD & David Schiff MD

Authors
  1. Haroon Ahmad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Schiff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haroon Ahmad MD.

Ethics declarations

Conflict of Interest

Haroon Ahmad declares that he has no conflict of interest.

David Schiff previously served as site PI for a trial (funded by Genentech) of bevacizumab in recurrent meningioma. His institution received per-subject payment for trial accrual.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmad, H., Schiff, D. Multimodality Therapy of Patients with Refractory Meningiomas. Curr. Treat. Options in Oncol. 20, 50 (2019). https://doi.org/10.1007/s11864-019-0648-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0648-z

Keywords

Search

Navigation